Nanobodies targeting CAIX antigen and their applications
By designing specific anti-CAIX single domain antibodies and using their high affinity to bind to CAIX, the problems of high production cost and high drug burden of existing targeted CAIX antibodies have been solved, and effective inhibition and simplicity of production of solid tumors are achieved.
Patent Information
- Application Number
- CN202080064128.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-09-10
- Filing Date
- 2020-08-25
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2040-08-25
AI Technical Summary
The existing targeted CAIX antibody drugs are costly in the production process and have a heavy burden on patients to take medication. They lack simple production methods with high specificity and clinical efficacy.
An anti-CAIX single domain antibody was developed that contains a complementary determining region CDR region of a specific VHH chain, designed with a high CAIX binding affinity and reduces production costs through simplified production methods. .
It has achieved good inhibitory effect on solid tumors, and improved the specificity of drugs, simplified the production process, reduced costs, and reduced the drug burden of patients.
Smart Images

Figure GDA0004912510490000141 
Figure GDA0004912510490000151 
Figure GDA0004912510490000211
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine or biopharmaceutical technology, and more specifically to a nano antibody targeting CAIX antigen and application thereof. Background Art
[0002] CAIX is a transmembrane protein expressed in a variety of solid tumor cells. The main function of CAIX is to maintain the homeostasis of intracellular pH under hypoxic conditions common in solid tumors. The expression of CAIX in tumor cells is considered to be a marker protein for hypoxia in the tumor environment and a poor prognosis for patients. Common tumor types expressing CAIX include cervical cancer, kidney cancer, brain cancer, head and neck cancer, esophageal cancer, intestinal cancer, breast cancer, ovarian cancer, endometrial cancer, bladder cancer, etc. In normal tissues, CAIX is mainly expressed in epithelial cells of the bile duct and small intestine, as well as gastric epithelial cells, etc., but unlike tumor cells, CAIX expressed in normal tissues is mainly localized in the cytoplasm. Therefore, CAIX is an ideal therapeutic target for targeted therapy.
[0003] Currently, the two most advanced antibody drugs targeting CAIX antigen have both entered the clinical stage. One is the Girentuximab human-mouse chimeric monoclonal antibody drug developed by Wilex AG, which is currently used for the clinical diagnosis of renal cell carcinoma in Phase III clinical trials (NCT03849118); the other is the antibody-drug conjugate targeting CAIX (CA9-ADC) jointly developed by Bayer AG, Morphosys and Seattle Genetics. The clinical trial has been advanced to Phase I for the clinical treatment of solid tumors. In addition, the Dana-Farber Cancer Institute has also developed a CAR-T therapy targeting CAIX, which is currently in the preclinical research stage.
[0004] Developing an anti-CAIX nanoantibody with better specificity, better clinical efficacy, and easy production, which can reduce production costs and alleviate the medication burden on patients has become an urgent problem to be solved. Summary of the invention
[0005] The object of the present invention is to provide an anti-CAIX single domain antibody and application thereof.
[0006] Specifically, the purpose of the present invention is to provide a single domain antibody that has a good inhibitory effect on solid tumors and has good specificity.
[0007] In a first aspect of the present invention, a complementary determining region (CDR) of an anti-CAIX single domain antibody VHH chain is provided, wherein the complementary determining region (CDR) of the VHH chain comprises:
[0008] CDR1 shown in SEQ ID NO.5n+1,
[0009] CDR2 shown in SEQ ID NO.5n+2, and
[0010] CDR3 shown in SEQ ID NO.5n+3;
[0011] wherein each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11;
[0012] Among them, any one of the above amino acid sequences also includes a derivative sequence that is optionally added, deleted, modified and / or substituted with at least one amino acid and can retain the CAIX binding affinity.
[0013] In another preferred embodiment, the CDR1, CDR2 and CDR3 are separated by framework regions FR1, FR2, FR3 and FR4.
[0014] The second aspect of the present invention provides a VHH chain of an anti-CAIX single domain antibody, wherein the VHH chain comprises a framework region FR and a complementarity determining region CDR as described in the first aspect of the present invention.
[0015] In another preferred embodiment, the framework region FR includes:
[0016] (a) FR1 shown in SEQ ID NO.4m+71, FR2 shown in SEQ ID NO.4m+72, FR3 shown in SEQ ID NO.4m+73, FR4 shown in SEQ ID NO.4m+74; wherein each m is independently 0, 1, 2, 3 or 4.
[0017] In another preferred embodiment, the amino acid sequence of the VHH chain of the anti-CAIX single domain antibody is as follows:
[0018] (i) as shown in SEQ ID NO.5n+4, wherein each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11; or
[0019] (ii) as shown in SEQ ID NO. 2m+61, wherein each m is independently 0, 1, 2, 3 or 4.
[0020] In another preferred embodiment, the VHH chain of the anti-CAIX single domain antibody is as shown in SEQ ID NO.4, 9, 14, 19, 24, 29, 34, 39, 44, 49, 54, 59, 61, 63, 65, 67 or 69.
[0021] In addition, a heavy chain variable region of an anti-CAIX single domain antibody is provided, wherein the heavy chain variable region comprises:
[0022] CDR1 shown in SEQ ID NO.5n+1,
[0023] CDR2 shown in SEQ ID NO.5n+2, and
[0024] CDR3 shown in SEQ ID NO.5n+3;
[0025] wherein each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11.
[0026] The third aspect of the present invention provides an anti-CAIX single domain antibody, which is a single domain antibody against the CAIX epitope and has the VHH chain described in the second aspect of the present invention.
[0027] In another preferred embodiment, the anti-CAIX single domain antibody includes a monomer, a bivalent body (bivalent antibody), and / or a multivalent body (multivalent antibody).
[0028] In another preferred embodiment, the anti-CAIX single domain antibody comprises one or more strands having:
[0029] (i) a VHH chain having an amino acid sequence as shown in SEQ ID NO. 5n+4, wherein each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11; and / or
[0030] (ii) A VHH chain having an amino acid sequence as shown in SEQ ID NO. 2m+61, wherein each m is independently 0, 1, 2, 3 or 4.
[0031] In another preferred example, the VHH chain sequence of the anti-CAIX single domain antibody is as shown in SEQ ID NO.4, 9, 14, 19, 24, 29, 34, 39, 44, 49, 54, 59, 61, 63, 65, 67 or 69.
[0032] In another preferred example, the anti-CAIX single domain antibody comprises two VHH chains having an amino acid sequence as shown in SEQ ID NO. 4, 9, 14, 19, 24, 29, 34, 39, 44, 49, 54, 59, 61, 63, 65, 67 or 69.
[0033] In another preferred example, the anti-CAIX single domain antibody has a VHH chain with an amino acid sequence as shown in SEQ ID NO. 4, 9, 14, 19, 24, 29, 34, 39, 44, 49, 54, 59, 61, 63, 65, 67 or 69.
[0034] In another preferred embodiment, the two VHH chains having the amino acid sequence shown in SEQ ID NO. 4, 9, 14, 19, 24, 29, 34, 39, 44, 49, 54, 59, 61, 63, 65, 67 or 69 are connected by a linker.
[0035] In a preferred embodiment of the present invention, the linker is selected from the following sequences: a S b ) x —(G m S n ) y , where a, b, m, n, x, y = 0 or 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 (preferably, a = 4 and b = 1, m = 3 and n = 1).
[0036] In a preferred example of the present invention, the linker is selected from the following group: GGGGSGGGS (SEQ ID NO.91), GS (SEQ ID NO.92), and GGGGS (SEQ ID NO.93).
[0037] In another preferred example, the amino acid sequence of the anti-CAIX single domain antibody is shown in SEQ ID NO.61, 63, 65, 67 or 69.
[0038] The fourth aspect of the present invention provides a polynucleotide, which encodes a protein selected from the following group: the CDR region of the anti-CAIX single domain antibody VHH chain described in the first aspect of the present invention, the VHH chain of the anti-CAIX single domain antibody described in the second aspect of the present invention, or the anti-CAIX single domain antibody described in the third aspect of the present invention.
[0039] In another preferred embodiment, the polynucleotide has:
[0040] (i) the nucleotide sequence shown in SEQ ID NO.5n+5, wherein each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11; or
[0041] (ii) The nucleotide sequence shown in SEQ ID NO. 2m+62, wherein each m is independently 0, 1, 2, 3 or 4.
[0042] In another preferred embodiment, the polynucleotide has a nucleotide sequence as shown in SEQ ID NO.5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 62, 64, 66, 68 or 70.
[0043] In another preferred embodiment, the polynucleotide includes DNA or RNA.
[0044] The fifth aspect of the present invention provides an expression vector, wherein the expression vector contains the polynucleotide described in the fourth aspect of the present invention.
[0045] In another preferred embodiment, the expression vector is selected from the following group: DNA, RNA, viral vector, plasmid, transposon, other gene transfer systems, or a combination thereof.
[0046] Preferably, the expression vector comprises a viral vector, such as a lentivirus, an adenovirus, an AAV virus, a retrovirus, or a combination thereof.
[0047] The sixth aspect of the present invention provides a host cell, wherein the host cell contains the expression vector described in the fifth aspect of the present invention, or the polynucleotide described in the fourth aspect of the present invention is integrated into its genome.
[0048] In another preferred embodiment, the host cell includes a prokaryotic cell or a eukaryotic cell.
[0049] In another preferred embodiment, the host cell is selected from the following group: Escherichia coli, yeast cells, mammalian cells, bacteriophages, or a combination thereof.
[0050] In another preferred embodiment, the prokaryotic cell is selected from the group consisting of Escherichia coli, Bacillus subtilis, lactic acid bacteria, Streptomyces, Proteus mirabilis, or a combination thereof.
[0051] In another preferred embodiment, the eukaryotic cell is selected from the group consisting of Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Trichoderma, or a combination thereof.
[0052] In another preferred embodiment, the eukaryotic cells are selected from the following groups: insect cells such as fall armyworm, BHK cells, CHO cells, COS cells, myeloma cells, or a combination thereof.
[0053] In another preferred embodiment, the host cell is preferably a mammalian cell, more preferably a HEK293 cell, a CHO cell, a BHK cell, a NSO cell or a COS cell.
[0054] In another preferred embodiment, the host cell is Pichia pastoris.
[0055] A seventh aspect of the present invention provides a method for producing an anti-CAIX single domain antibody, comprising the steps of:
[0056] (a) culturing the host cell according to the sixth aspect of the present invention under conditions suitable for producing the single domain antibody, thereby obtaining a culture containing the anti-CAIX single domain antibody; and
[0057] (b) isolating or recovering the anti-CAIX single domain antibody from the culture; and
[0058] (c) optionally, purifying and / or modifying the CAIX single domain antibody obtained in step (b).
[0059] In another preferred embodiment, the anti-CAIX single domain antibody has an amino acid sequence as shown in SEQ ID NO.4, 9, 14, 19, 24, 29, 34, 39, 44, 49, 54, 59, 61, 63, 65, 67 or 69.
[0060] In another preferred example, the anti-CAIX single domain antibody has an amino acid sequence as shown in SEQ ID NO.61, 63, 65, 67 or 69.
[0061] The eighth aspect of the present invention provides an immunoconjugate, the immunoconjugate comprising:
[0062] (a) the VHH chain of the anti-CAIX single domain antibody according to the second aspect of the present invention, or the anti-CAIX single domain antibody according to the third aspect of the present invention; and
[0063] (b) a conjugated moiety selected from the group consisting of a detectable label, a drug, a toxin, a cytokine, a radionuclide, an enzyme, a gold nanoparticle / nanorod, a nanomagnetic particle, a viral coat protein or a VLP, or a combination thereof.
[0064] In another preferred embodiment, the radioactive nuclides include:
[0065] (i) a diagnostic isotope selected from the group consisting of Tc-99m, Ga-68, F-18, I-123, I-125, I-131, In-111, Ga-67, Cu-64, Zr-89, C-11, Lu-177, Re-188, or a combination thereof; and / or
[0066] (ii) therapeutic isotopes, wherein the therapeutic isotopes are selected from the group consisting of Lu-177, Y-90, Ac-225, As-211, Bi-212, Bi-213, Cs-137, Cr-51, Co-60, Dy-165, Er-169, Fm-255, Au-198, Ho-166, I-125, I-131, Ir-192, Fe-59, Pb-212, Mo-99, Pd-103, P-32, K-42, Re-186, Re-188, Sm-153, Ra223, Ru-106, Na24, Sr89, Tb-149, Th-227, Xe-133 Yb-169, Yb-177, or a combination thereof.
[0067] In another preferred embodiment, the coupling moiety is a drug or a toxin.
[0068] In another preferred embodiment, the drug is a cytotoxic drug.
[0069] In another preferred embodiment, the cytotoxic drug is selected from the following group: anti-tubulin drugs, DNA minor groove binding agents, DNA replication inhibitors, alkylating agents, antibiotics, folic acid antagonists, antimetabolites, chemosensitizers, topoisomerase inhibitors, vinca alkaloids, or a combination thereof.
[0070] In another preferred embodiment, examples of particularly useful cytotoxic drugs include, for example, DNA minor groove binding agents, DNA alkylating agents, and tubulin inhibitors, typical cytotoxic drugs include, for example, auristatins, camptothecins, duocarmycins, etoposides, maytansines and maytansinoids (e.g., DM1 and DM4), taxanes, benzodiazepines or benzodiazepine containing drugs (e.g., pyrrolo[1,4]benzodiazepines (PBDs), indolinobenzodiazepines and oxazolidinobenzodiazepines), vinca alkaloids, or a combination thereof.
[0071] In another preferred embodiment, the toxin is selected from the group consisting of auristatins (e.g., auristatin E, auristatin F, MMAE and MMAF), chlortetracycline, maytansyl, ricin, ricin A-chain, combretastatin, duocarmycin, dolastatin, adriamycin, daunorubicin, paclitaxel, cisplatin, cc1065, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxyproline, succinimidyl, tadalafil, tadalafil, succinimidyl ... anthracnose dione, actinomycin, diphtheria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha-sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotonin, calicheamicin, Sapaonaria officinalis inhibitor, glucocorticoids, or a combination thereof.
[0072] In another preferred embodiment, the coupling moiety is a detectable label.
[0073] In another preferred embodiment, the coupling portion is selected from the following group: fluorescent or luminescent markers, radioactive markers, MRI (magnetic resonance imaging) or CT (computer tomography) contrast agents, or enzymes capable of producing detectable products, radionuclides, biotoxins, cytokines (such as IL-2, etc.), antibodies, antibody Fc fragments, antibody scFv fragments, gold nanoparticles / nanorods, viral particles, liposomes, nanomagnetic particles, prodrug activating enzymes (for example, DT-diaphorase (DTD) or biphenyl hydrolase-like protein (BPHL)), chemotherapeutic agents (for example, cisplatin) or any form of nanoparticles.
[0074] In another preferred embodiment, the immunoconjugate contains: a multivalent (eg, bivalent) VHH chain of the anti-CAIX single domain antibody as described in the second aspect of the present invention, and an anti-CAIX single domain antibody as described in the third aspect of the present invention.
[0075] In another preferred embodiment, the multivalency refers to the presence of multiple repeats of the VHH chain of the anti-CAIX single domain antibody described in the second aspect of the present invention or the anti-CAIX single domain antibody described in the third aspect of the present invention in the amino acid sequence of the immunoconjugate.
[0076] The ninth aspect of the present invention provides the use of the VHH chain of the anti-CAIX single domain antibody according to the second aspect of the present invention and the anti-CAIX single domain antibody according to the third aspect of the present invention for preparing:
[0077] (a) Antibody-drug conjugates (ADCs), monoclonal antibody drugs, bispecific / multispecific antibody drugs, cell therapy-related drugs, etc.
[0078] (b) Drugs used to diagnose or treat diseases or conditions associated with CAIX.
[0079] The tenth aspect of the present invention provides a pharmaceutical composition, which contains:
[0080] (i) the complementarity determining region (CDR) of the anti-CAIX single domain antibody VHH chain according to the first aspect of the present invention, the VHH chain of the anti-CAIX single domain antibody according to the second aspect of the present invention, the anti-CAIX single domain antibody according to the third aspect of the present invention, or the immunoconjugate according to the eighth aspect of the present invention; and
[0081] (ii) a pharmaceutically acceptable carrier.
[0082] In another preferred embodiment, the conjugated portion of the immunoconjugate is a drug, a toxin, and / or a therapeutic isotope.
[0083] In another preferred embodiment, the pharmaceutical composition further contains other drugs for treating tumors, such as cytotoxic drugs.
[0084] In another preferred embodiment, the pharmaceutical composition is in the form of an injection.
[0085] In another preferred embodiment, the pharmaceutical composition is used to prepare a drug for treating a disease or condition associated with CAIX, wherein the disease or condition includes a tumor or cancer.
[0086] In another preferred embodiment, the tumor or cancer includes, but is not limited to, one or more of cervical cancer, kidney cancer, brain cancer, head and neck cancer, esophageal cancer, intestinal cancer, breast cancer, ovarian cancer, endometrial cancer, and bladder cancer.
[0087] The eleventh aspect of the present invention provides one or more uses of the anti-CAIX single domain antibody according to the third aspect of the present invention; for preparing:
[0088] (a) Used for the preparation of antibody-drug conjugates (ADCs), monoclonal antibody drugs, bispecific / multispecific antibody drugs, cell therapy-related drugs, etc. targeting CAIX antigen;
[0089] (b) drugs used to diagnose or treat diseases or conditions associated with CAIX;
[0090] (c) for detecting human CAIX molecules;
[0091] (d) used for flow cytometry;
[0092] (e) used for cell immunofluorescence detection;
[0093] (f) for treating tumors;
[0094] (g) Used in tumor diagnosis.
[0095] In another preferred embodiment, the use is diagnostic and / or non-diagnostic, and / or therapeutic and / or non-therapeutic.
[0096] The twelfth aspect of the present invention provides an antibody comprising one or more VHH chains of the anti-CAIX single domain antibody according to the second aspect of the present invention.
[0097] In another preferred embodiment, the antibody comprises two VHH chains of the anti-CAIX single domain antibody described in the second aspect of the present invention.
[0098] In another preferred embodiment, the antibody has the heavy chain variable region VHH as described in the second aspect of the present invention.
[0099] In another preferred embodiment, the antibody is a single domain antibody.
[0100] In another preferred embodiment, the antibody is a bispecific antibody (simultaneously targeting CAIX and other tumor-associated antigens or immune cell activation-associated antigens, etc.).
[0101] In another preferred embodiment, the antibody is a multispecific antibody (simultaneously targeting CAIX and other tumor-associated antigens or immune cell activation-associated antigens, etc.).
[0102] The thirteenth aspect of the present invention provides a recombinant protein, wherein the recombinant protein has:
[0103] (i) the VHH chain according to the second aspect of the present invention or the anti-CAIX single domain antibody according to the third aspect of the present invention; and
[0104] (ii) optionally a tag sequence to facilitate expression and / or purification.
[0105] In another preferred embodiment, the tag sequence includes an Fc tag, an HA tag and a 6His tag.
[0106] In another preferred embodiment, the recombinant protein specifically binds to the CAIX protein.
[0107] In the fourteenth aspect of the present invention, there is provided a use of the VHH chain of the anti-CAIX single domain antibody as described in the second aspect of the present invention, the anti-CAIX single domain antibody as described in the third aspect of the present invention, or the immunoconjugate as described in the eighth aspect of the present invention for preparing a medicament, a reagent, a detection plate or a kit;
[0108] Wherein, the reagent, detection plate or kit is used for: detecting CAIX protein in a sample;
[0109] Wherein, the medicament is used to treat or prevent a disease or condition associated with CAIX.
[0110] In another preferred embodiment, the detection includes flow cytometry detection and cell immunofluorescence detection.
[0111] In another preferred embodiment, the disease or disorder includes a tumor or cancer.
[0112] In another preferred embodiment, the tumor or cancer includes, but is not limited to, one or more of cervical cancer, kidney cancer, brain cancer, head and neck cancer, esophageal cancer, intestinal cancer, breast cancer, ovarian cancer, endometrial cancer, and bladder cancer.
[0113] The fifteenth aspect of the present invention provides a method for treating a disease, the method comprising administering the single domain antibody described in the third aspect of the present invention or the immunoconjugate described in the eighth aspect of the present invention to a subject in need thereof.
[0114] In another preferred embodiment, the subject includes mammals, such as humans, mice, rabbits, and monkeys.
[0115] In a sixteenth aspect of the present invention, a method for detecting CAIX protein in a sample is provided, the method comprising the steps of:
[0116] (1) contacting a sample with the VHH chain described in the second aspect of the present invention, the single domain antibody described in the third aspect of the present invention, or the immunoconjugate described in the eighth aspect of the present invention;
[0117] (2) Detecting whether an antigen-antibody complex is formed, wherein the formation of the complex indicates the presence of CAIX protein in the sample.
[0118] In another preferred embodiment, the method is a non-diagnostic and / or non-therapeutic method.
[0119] In the seventeenth aspect of the present invention, a CAIX protein detection reagent is provided, wherein the detection reagent comprises:
[0120] (i) the VHH chain of the second aspect of the present invention, the single domain antibody of the third aspect of the present invention, or the immunoconjugate of the eighth aspect of the present invention; and
[0121] (ii) A carrier that is acceptable in detection.
[0122] In another preferred embodiment, the conjugated portion of the immunoconjugate is a diagnostic isotope.
[0123] In another preferred embodiment, the test-acceptable carrier is a non-toxic, inert aqueous carrier medium.
[0124] In another preferred embodiment, the detection reagent is one or more reagents selected from the following group: isotope tracers, contrast agents, flow cytometry detection reagents, cell immunofluorescence detection reagents, nanomagnetic particles and imaging agents.
[0125] In another preferred embodiment, the detection reagent is used for in vivo detection.
[0126] In another preferred embodiment, the dosage form of the detection reagent is liquid or powder (such as aqueous solution, injection, lyophilized powder, tablet, buccal preparation, inhaler).
[0127] The eighteenth aspect of the present invention provides a kit for detecting CAIX protein, wherein the kit contains the immunoconjugate described in the eighth aspect of the present invention or the detection reagent described in the seventeenth aspect of the present invention, and instructions.
[0128] In another preferred embodiment, the instructions state that the kit is used for non-invasively detecting the expression of CAIX in a subject to be tested.
[0129] The nineteenth aspect of the present invention provides a use of the immunoconjugate described in the eighth aspect of the present invention for preparing a contrast agent for detecting CAIX protein in vivo.
[0130] In another preferred example, the detection is used for the diagnosis or prognosis of cancer.
[0131] The twentieth aspect of the present invention provides a CAR-T cell, wherein the CAR-T cell expresses a chimeric antigen receptor CAR, and the antigen binding domain of the CAR comprises the VHH chain of the anti-CAIX single domain antibody described in the second aspect of the present invention or the anti-CAIX single domain antibody described in the third aspect of the present invention.
[0132] The twenty-first aspect of the present invention provides a preparation, which contains the CAR-T cells described in the twentieth aspect of the present invention, and a pharmaceutically acceptable carrier, diluent or excipient.
[0133] In another preferred embodiment, the preparation is a liquid preparation.
[0134] In another preferred embodiment, the dosage form of the preparation includes injection.
[0135] In another preferred embodiment, the concentration of the CAR-T cells in the preparation is 1×10 3 -1×10 8 cells / ml, preferably 1×10 4 -1×10 7cells / ml.
[0136] In the twenty-second aspect of the present invention, there is provided a framework region FR of an anti-CAIX single domain antibody VHH chain, wherein the framework region FR of the VHH chain consists of:
[0137] (a) FR1 shown in SEQ ID NO.4m+71, FR2 shown in SEQ ID NO.4m+72, FR3 shown in SEQ ID NO.4m+73, and FR4 shown in SEQ ID NO.4m+74; wherein each m is independently 0, 1, 2, 3 or 4.
[0138] The twenty-third aspect of the present invention provides a method for treating a disease or condition associated with CAIX, comprising administering the pharmaceutical composition of the tenth aspect of the present invention to a subject in need thereof.
[0139] In another preferred embodiment, the subject includes mammals, such as humans.
[0140] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS
[0141] Figure 1 A graph showing the results of the detection of the binding force between CAIX nanobody and CHO-hCAIX cells.
[0142] Figure 2 A graph showing the results of affinity testing of humanized nanobodies to CHO-hCAIX cells.
[0143] Figure 3 A graph showing the results of affinity testing of humanized nanobodies to CHO-cyCAIX cells.
[0144] Figure 4 A graph showing the results of affinity testing of humanized nanobodies to CHO-mCAIX cells. DETAILED DESCRIPTION
[0145] The inventors have conducted extensive and in-depth research and, after a large number of screenings, unexpectedly discovered a class of anti-CAIX single-domain antibodies for the first time. Experimental results show that the single-domain antibodies of the present invention can specifically recognize CAIX and can bind to CAIX protein or CAIX-positive cells with very high affinity. The single-domain antibodies of the present invention are easy to generate. Thus, the present invention is completed.
[0146] Specifically, the present invention uses CAIX antigen to immunize alpacas, extract RNA from alpacas' peripheral lymphocytes and reverse it into cDNA to construct a yeast screening library of CAIX nanoantibodies. CAIX-specific binding antibodies are obtained after magnetic bead screening and flow enrichment of the yeast library. The antibodies obtained from the preliminary screening are expressed and prepared, and the CAIX antigen affinity is determined at the protein level and the cell level, respectively, laying the foundation for the next step of drug development.
[0147] the term
[0148] As used herein, the terms "single domain antibody of the present invention", "single domain antibody of the present invention", "anti-CAIX antibody of the present invention", "CAIX single domain antibody of the present invention", and "anti-CAIX single domain antibody" have the same meaning and are used interchangeably, and all refer to single domain antibodies that specifically recognize and bind to CAIX (including human CAIX). Preferably, the variable region of the single domain antibody of the present invention has CDR1 shown in SEQ ID NO.5n+1, CDR2 shown in SEQ ID NO.5n+2, and CDR3 shown in SEQ ID NO.5n+3, wherein each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11. More preferably, the amino acid sequence of the VHH chain of the single domain antibody of the present invention is as follows: (i) as shown in SEQ ID NO.5n+4, wherein each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11; or (ii) as shown in SEQ ID NO.2m+61, wherein each m is independently 0, 1, 2, 3 or 4. Even more preferably, the framework region of the single domain antibody of the present invention is composed of (a) FR1 shown in SEQ ID NO.4m+71, FR2 shown in SEQ ID NO.4m+72, FR3 shown in SEQ ID NO.4m+73, and FR4 shown in SEQ ID NO.4m+74; wherein each m is independently 0, 1, 2, 3 or 4.
[0149] As used herein, the term "antibody" or "immunoglobulin" is a heterotetrameric glycoprotein of about 150,000 daltons with identical structural features, consisting of two identical light chains (L) and two identical heavy chains (H). Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide bonds between the heavy chains of different immunoglobulin isotypes varies. Each heavy and light chain also has regularly spaced intrachain disulfide bonds. Each heavy chain has a variable region (VH) at one end, followed by multiple constant regions. Each light chain has a variable region (VL) at one end and a constant region at the other end; the constant region of the light chain is opposite to the first constant region of the heavy chain, and the variable region of the light chain is opposite to the variable region of the heavy chain. Specific amino acid residues form an interface between the variable regions of the light and heavy chains.
[0150] As used herein, the terms "single domain antibody", "VHH", "nanobody", "single domain antibody" (sdAb, or nanobody) have the same meaning and are used interchangeably, referring to cloning the variable region of the antibody heavy chain to construct a single domain antibody (VHH) consisting of only one heavy chain variable region, which is the smallest antigen-binding fragment with complete functions. Usually, an antibody naturally lacking the light chain and heavy chain constant region 1 (CH1) is first obtained, and then the variable region of the antibody heavy chain is cloned to construct a single domain antibody (VHH) consisting of only one heavy chain variable region.
[0151] As used herein, the term "variable" means that some parts of the variable region in an antibody are different in sequence, which forms the binding and specificity of various specific antibodies to their specific antigens. However, variability is not evenly distributed throughout the variable region of an antibody. It is concentrated in three fragments called complementary determining regions (CDRs) or hypervariable regions in the variable regions of light and heavy chains. The more conservative part of the variable region is called the framework region (FR). The variable regions of natural heavy and light chains each contain four FR regions, which are roughly in a β-folded configuration, connected by three CDRs forming a connecting loop, and in some cases can form a partial β-folded structure. The CDRs in each chain are closely together through the FR region and together with the CDRs of the other chain form the antigen-binding site of the antibody (see Kabat et al., NIH Publ. No. 91-3242, Volume I, 647-669 pages (1991)). The constant region does not directly participate in the binding of the antibody to the antigen, but they exhibit different effector functions, such as participating in the antibody's antibody-dependent cytotoxicity.
[0152] As known to those skilled in the art, immunoconjugates and fusion expression products include: drugs, toxins, cytokines, radionuclides, enzymes and other diagnostic or therapeutic molecules combined with the antibodies or fragments of the present invention to form conjugates. The present invention also includes cell surface markers or antigens combined with the anti-CAIX antibodies or fragments thereof.
[0153] As used herein, the term "heavy chain variable region" is used interchangeably with "VH".
[0154] As used herein, the term "variable region" and "complementarity determining region (CDR)" are used interchangeably.
[0155] In a preferred embodiment of the present invention, the heavy chain variable region of the antibody includes three complementarity determining regions CDR1, CDR2, and CDR3.
[0156] In a preferred embodiment of the present invention, the heavy chain of the antibody includes the above-mentioned heavy chain variable region and heavy chain constant region.
[0157] In the present invention, the terms "antibodies of the present invention", "proteins of the present invention", or "polypeptides of the present invention" are used interchangeably, and all refer to polypeptides that specifically bind to the CAIX protein, such as proteins or polypeptides having a heavy chain variable region. They may or may not contain an initial methionine.
[0158] The present invention also provides other proteins or fusion expression products having the antibodies of the present invention. Specifically, the present invention includes any protein or protein conjugate and fusion expression product (i.e., immunoconjugate and fusion expression product) having a heavy chain containing a variable region, as long as the variable region is identical to or at least 90% homologous to the heavy chain variable region of the antibodies of the present invention, preferably at least 95% homologous.
[0159] Generally, the antigen binding properties of an antibody can be described by three specific regions located in the variable region of the heavy chain, called the variable region (CDR). This segment is divided into four framework regions (FR). The amino acid sequences of the four FRs are relatively conservative and do not directly participate in the binding reaction. These CDRs form a ring structure, and the β-folds formed by the FRs in between are close to each other in spatial structure. The CDRs on the heavy chain and the CDRs on the corresponding light chain constitute the antigen binding site of the antibody. The amino acid sequences of antibodies of the same type can be compared to determine which amino acids constitute the FR or CDR region.
[0160] The variable regions of the heavy chains of the antibodies of the present invention are of particular interest because they are at least partially involved in binding to antigen. Therefore, the present invention includes molecules having antibody heavy chain variable regions with CDRs, as long as their CDRs have more than 90% (preferably more than 95%, and most preferably more than 98%) homology with the CDRs identified herein.
[0161] The present invention includes not only complete antibodies, but also fragments of antibodies with immunological activity or fusion proteins formed by antibodies and other sequences. Therefore, the present invention also includes fragments, derivatives and analogs of the antibodies.
[0162] As used herein, the terms "fragment", "derivative" and "analog" refer to polypeptides that substantially retain the same biological function or activity as the antibodies of the present invention. The polypeptide fragments, derivatives or analogs of the present invention may be (i) polypeptides in which one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) are substituted, and such substituted amino acid residues may or may not be encoded by the genetic code, or (ii) polypeptides having a substitution group in one or more amino acid residues, or (iii) polypeptides formed by fusion of a mature polypeptide with another compound (such as a compound that prolongs the half-life of the polypeptide, such as polyethylene glycol), or (iv) polypeptides formed by fusion of an additional amino acid sequence to the polypeptide sequence (such as a leader sequence or secretory sequence or a sequence or proprotein sequence used to purify the polypeptide, or a fusion protein formed with a 6His tag). According to the teachings herein, these fragments, derivatives and analogs are within the scope known to those skilled in the art.
[0163] The antibody of the present invention refers to a polypeptide having CAIX binding activity and including the above-mentioned CDR region. The term also includes variant forms of polypeptides having the same function as the antibody of the present invention and including the above-mentioned CDR region. These variant forms include (but are not limited to): one or more (usually 1-50, preferably 1-30, more preferably 1-20, and most preferably 1-10) amino acid deletions, insertions and / or substitutions, and addition of one or several (usually within 20, preferably within 10, and more preferably within 5) amino acids at the C-terminus and / or N-terminus. For example, in the art, when amino acids with similar or similar properties are substituted, the function of the protein is usually not changed. For another example, adding one or several amino acids to the C-terminus and / or N-terminus usually does not change the function of the protein. The term also includes active fragments and active derivatives of the antibodies of the present invention.
[0164] Variant forms of the polypeptide include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, proteins encoded by DNA that can hybridize with the encoding DNA of the antibody of the present invention under high or low stringency conditions, and polypeptides or proteins obtained using antiserum against the antibody of the present invention.
[0165] The present invention also provides other polypeptides, such as fusion proteins comprising single domain antibodies or fragments thereof. In addition to almost full-length polypeptides, the present invention also includes fragments of single domain antibodies of the present invention. Typically, the fragment has at least about 50 consecutive amino acids of the antibody of the present invention, preferably at least about 50 consecutive amino acids, more preferably at least about 80 consecutive amino acids, and most preferably at least about 100 consecutive amino acids.
[0166] In the present invention, "conservative variants of the antibodies of the present invention" refer to polypeptides formed by replacing at most 10, preferably at most 8, more preferably at most 5, and most preferably at most 3 amino acids with amino acids having similar or similar properties compared to the amino acid sequence of the antibodies of the present invention. These conservative variant polypeptides are preferably generated by amino acid substitution according to Table 1.
[0167] Table 1
[0168]
[0169]
[0170] The present invention also provides a polynucleotide molecule encoding the above-mentioned antibody or its fragment or its fusion protein. The polynucleotide of the present invention can be in the form of DNA or RNA. The DNA form includes cDNA, genomic DNA or artificially synthesized DNA. The DNA can be single-stranded or double-stranded. The DNA can be a coding strand or a non-coding strand.
[0171] The polynucleotide encoding the mature polypeptide of the present invention includes: a coding sequence encoding only a mature polypeptide; a coding sequence of a mature polypeptide and various additional coding sequences; a coding sequence of a mature polypeptide (and optional additional coding sequences) and non-coding sequences.
[0172] The term "polynucleotide encoding a polypeptide" may include a polynucleotide encoding the polypeptide, or may include additional coding and / or non-coding sequences.
[0173] The present invention also relates to polynucleotides that hybridize with the above sequences and have at least 50%, preferably at least 70%, and more preferably at least 80% identity between the two sequences. The present invention particularly relates to polynucleotides that can hybridize with the polynucleotides of the present invention under stringent conditions. In the present invention, "stringent conditions" refer to: (1) hybridization and elution at relatively low ionic strength and relatively high temperature, such as 0.2×SSC, 0.1% SDS, 60°C; or (2) addition of denaturing agents during hybridization, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% Ficoll, 42°C, etc.; or (3) hybridization occurs only when the identity between the two sequences is at least 90%, preferably at least 95%. In addition, the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide.
[0174] The full-length nucleotide sequence of the antibody of the present invention or its fragment can usually be obtained by PCR amplification, recombination or artificial synthesis. A feasible method is to synthesize the relevant sequence by artificial synthesis, especially when the fragment length is short. Usually, a fragment with a very long sequence can be obtained by synthesizing multiple small fragments first and then connecting them. In addition, the coding sequence of the heavy chain and the expression tag (such as 6His) can be fused together to form a fusion protein.
[0175] Once the relevant sequence is obtained, it can be obtained in large quantities by recombinant methods. This is usually done by cloning it into a vector, then transferring it into cells, and then isolating the relevant sequence from the proliferated host cells by conventional methods. The biomolecules (nucleic acids, proteins, etc.) involved in the present invention include biomolecules in isolated form.
[0176] At present, the DNA sequence encoding the protein of the present invention (or its fragment, or its derivative) can be obtained completely by chemical synthesis. The DNA sequence can then be introduced into various existing DNA molecules (or vectors) and cells known in the art. In addition, mutations can also be introduced into the protein sequence of the present invention by chemical synthesis.
[0177] The present invention also relates to vectors comprising the above-mentioned appropriate DNA sequence and appropriate promoter or control sequence. These vectors can be used to transform appropriate host cells to enable them to express proteins.
[0178] Host cells can be prokaryotic cells, such as bacterial cells; or lower eukaryotic cells, such as yeast cells; or higher eukaryotic cells, such as mammalian cells. Representative examples include: Escherichia coli, Streptomyces; bacterial cells of Salmonella typhimurium; fungal cells such as yeast; insect cells of Drosophila S2 or Sf9; animal cells such as CHO, COS7, 293 cells, etc.
[0179] Transformation of host cells with recombinant DNA can be performed using conventional techniques well known to those skilled in the art. When the host is a prokaryotic organism such as Escherichia coli, competent cells that can absorb DNA can be harvested after the exponential growth phase and treated with the CaCl2 method, the steps used are well known in the art. Another method is to use MgCl2. If necessary, transformation can also be performed using electroporation. When the host is a eukaryotic organism, the following DNA transfection methods can be selected: calcium phosphate coprecipitation method, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.
[0180] The obtained transformant can be cultured by conventional methods to express the polypeptide encoded by the gene of the present invention. Depending on the host cell used, the culture medium used in the culture can be selected from various conventional culture media. Culture is carried out under conditions suitable for the growth of the host cells. After the host cells grow to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
[0181] The recombinant polypeptide in the above method can be expressed in the cell, on the cell membrane, or secreted outside the cell. If necessary, the recombinant protein can be separated and purified by various separation methods using its physical, chemical and other properties. These methods are well known to those skilled in the art. Examples of these methods include but are not limited to: conventional renaturation treatment, treatment with a protein precipitant (salting out method), centrifugation, osmotic sterilization, ultra-treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography techniques and combinations of these methods.
[0182] The antibodies of the invention may be used alone or in combination or conjugated to a detectable marker (for diagnostic purposes), a therapeutic agent, a PK (protein kinase) modifying moiety, or any combination of these.
[0183] Detectable labels for diagnostic purposes include, but are not limited to, fluorescent or luminescent labels, radioactive labels, MRI (magnetic resonance imaging) or CT (computed tomography) contrast agents, or enzymes capable of producing a detectable product.
[0184] Therapeutic agents that can be combined or coupled to the antibodies of the present invention include, but are not limited to: 1. radionuclides; 2. biological toxins; 3. cytokines such as IL-2, etc.; 4. gold nanoparticles / nanorods; 5. viral particles; 6. liposomes; 7. nanomagnetic particles; 8. prodrug activating enzymes (e.g., DT-diaphorase (DTD) or biphenyl hydrolase-like protein (BPHL)); 10. chemotherapeutic agents (e.g., cisplatin) or any form of nanoparticles, etc.
[0185] CAIX
[0186] CAIX is a transmembrane protein expressed in a variety of solid tumor cells. The main function of CAIX is to maintain the homeostasis of intracellular pH under hypoxic conditions common in solid tumors. The molecular weight of human CAIX is 49.7KDa and it is composed of 459 amino acids. CAIX is a type I transmembrane protein, which is divided into a signal peptide, a glycoprotein-like region, a carbonic anhydrase base domain, a transmembrane region, and an intracellular region. Among them, the extracellular carbonic anhydrase base domain is the enzymatic active region that regulates the homeostasis of intracellular pH.
[0187] Pharmaceutical composition
[0188] The present invention also provides a composition. Preferably, the composition is a pharmaceutical composition, which contains the above-mentioned antibody or its active fragment or its fusion protein, and a pharmaceutically acceptable carrier. Generally, these substances can be formulated in a non-toxic, inert and pharmaceutically acceptable aqueous carrier medium, wherein the pH is generally about 5-8, preferably about 6-8, although the pH value may vary depending on the properties of the formulated substance and the condition to be treated. The formulated pharmaceutical composition can be administered by conventional routes, including (but not limited to): intratumoral, intraperitoneal, intravenous, or local administration.
[0189] The pharmaceutical composition of the present invention can be directly used to bind to the CAIX protein molecule, and thus can be used to treat tumors. In addition, other therapeutic agents can also be used simultaneously.
[0190] The pharmaceutical composition of the present invention contains a safe and effective amount (such as 0.001-99wt%, preferably 0.01-90wt%, more preferably 0.1-80wt%) of the above-mentioned single-domain antibody (or its conjugate) of the present invention and a pharmaceutically acceptable carrier or excipient. Such carriers include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. The pharmaceutical preparation should match the mode of administration. The pharmaceutical composition of the present invention can be prepared in the form of an injection, for example, by conventional methods using physiological saline or an aqueous solution containing glucose and other adjuvants. Pharmaceutical compositions such as injections and solutions are preferably manufactured under sterile conditions. The dosage of the active ingredient is a therapeutically effective amount, for example, about 10 micrograms / kg body weight to about 50 milligrams / kg body weight per day. In addition, the polypeptide of the present invention can also be used with other therapeutic agents.
[0191] When using a pharmaceutical composition, a safe and effective amount of the immunoconjugate is administered to a mammal, wherein the safe and effective amount is usually at least about 10 micrograms / kg body weight, and in most cases does not exceed about 50 milligrams / kg body weight, preferably the dosage is about 10 micrograms / kg body weight to about 10 milligrams / kg body weight. Of course, the specific dosage should also take into account factors such as the route of administration and the patient's health status, which are all within the skill range of skilled physicians.
[0192] Anti-CAIX single domain antibody
[0193] In the present invention, the anti-CAIX single domain antibody includes a monomer, a bivalent body (bivalent antibody), and / or a multivalent body (multivalent antibody).
[0194] In a preferred embodiment of the present invention, the anti-CAIX single domain antibody comprises one, two or more strands having:
[0195] (i) a VHH chain having an amino acid sequence as shown in SEQ ID NO. 5n+4, wherein each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11; and / or
[0196] (ii) A VHH chain having an amino acid sequence as shown in SEQ ID NO. 2m+61, wherein each m is independently 0, 1, 2, 3 or 4.
[0197] Typically, the anti-CAIX single domain antibody comprises two VHH chains having an amino acid sequence as shown in SEQ ID NO. 4, 9, 14, 19, 24, 29, 34, 39, 44, 49, 54, 59, 61, 63, 65, 67 or 69.
[0198] Typically, the anti-CAIX single domain antibody has a VHH chain with an amino acid sequence as shown in SEQ ID NO. 4, 9, 14, 19, 24, 29, 34, 39, 44, 49, 54, 59, 61, 63, 65, 67 or 69.
[0199] In a preferred example of the present invention, the two VHH chains having the amino acid sequence shown in SEQ ID NO. 4, 9, 14, 19, 24, 29, 34, 39, 44, 49, 54, 59, 61, 63, 65, 67 or 69 are connected by a linker.
[0200] In a preferred embodiment of the present invention, the linker is selected from the following sequences: a S b ) x —(G m S n ) y , where a, b, m, n, x, y = 0 or 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 (preferably, a = 4 and b = 1, m = 3 and n = 1).
[0201] In a preferred example of the present invention, the linker is selected from the following group: GGGGSGGGS (SEQ ID NO.91), GS (SEQ ID NO.92), and GGGGS (SEQ ID NO.93).
[0202] In another preferred example, the amino acid sequence of the anti-CAIX single domain antibody is as shown in SEQ ID NO.61, 63, 65, 67 or 69.
[0203] Labeled single domain antibodies
[0204] In a preferred embodiment of the present invention, the single domain antibody carries a detectable marker. More preferably, the marker is selected from the group consisting of an isotope, a colloidal gold marker, a colored marker or a fluorescent marker.
[0205] Colloidal gold labeling can be performed using methods known to those skilled in the art. In a preferred embodiment of the present invention, the anti-CAIX single domain antibody is labeled with colloidal gold to obtain a colloidal gold labeled single domain antibody.
[0206] The anti-CAIX single-domain antibody of the present invention has good specificity and high titer.
[0207] Detection Methods
[0208] The present invention also relates to a method for detecting CAIX protein. The method generally comprises the following steps: obtaining a cell and / or tissue sample; dissolving the sample in a medium; and detecting the level of CAIX protein in the dissolved sample.
[0209] In the detection method of the present invention, the sample used is not particularly limited, and a representative example is a sample containing cells in a cell storage solution.
[0210] Reagent test kit
[0211] The present invention also provides a kit containing the antibody (or fragment thereof) or the detection plate of the present invention. In a preferred embodiment of the present invention, the kit further includes a container, instructions for use, a buffer, etc.
[0212] The present invention also provides a detection kit for detecting CAIX levels, which includes an antibody that recognizes CAIX protein, a lysis medium for dissolving a sample, and universal reagents and buffers required for detection, such as various buffers, detection markers, detection substrates, etc. The detection kit can be an in vitro diagnostic device.
[0213] application
[0214] As described above, the single domain antibody of the present invention has a wide range of biological and clinical application values, and its application involves multiple fields such as diagnosis and treatment of diseases related to CAIX, basic medical research, biological research, etc. A preferred application is for clinical diagnosis and targeted therapy of CAIX.
[0215] The main advantages of the present invention include:
[0216] (a) The single domain antibody of the present invention has a small molecular weight and good stability;
[0217] (b) The single domain antibody of the present invention has many advantages over traditional common normal antibodies in terms of drug development and diagnostic reagent development, such as good tissue infiltration, flexible administration methods, high degree of humanization, and easy recombinant protein transformation;
[0218] (c) The single domain antibody of the present invention can be easily produced.
[0219] The following specific examples further illustrate the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in (Sambrook and Russell et al., Molecular Cloning: A Laboratory Manual (Molecular Cloning-A Laboratory Manual) (3rd Edition) (2001) CSHL Press), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.
[0220] Example 1 Immunization and screening of CAIX nanobodies
[0221] After immunizing alpacas (Llama) with human CAIX antigen (purchased from AcroBiosystems), total RNA was extracted from the peripheral lymphocytes of the alpacas and reversed into cDNA. The PCR product of the cDNA was connected to the yeast display vector and then electroporated into Saccharomyces cerevisiae (purchased from ATCC) to construct a CAIX nanobody library.
[0222] CAIX protein (purchased from AcroBiosystems) was labeled according to the instructions of the biotin labeling kit (purchased from Thermo). After the amplified CAIX nanoantibody yeast library was labeled with biotin-labeled CAIX protein, positively labeled yeast was enriched using magnetic beads. After the yeast cells enriched with magnetic beads were amplified, 1:200 diluted anti-c-Myc antibody (purchased from Thermo) and appropriate amount of biotin-labeled CAIX antigen were added for staining. After the yeast was washed with PBS, 1:500 diluted Goat-Anti-mouse IgG (H+L) Alexa Fluor Plus 488 (purchased from Invitrogen) and streptavidin APC Conjugate fluorescent antibody (purchased from Invitrogen) were added and incubated for 15 minutes. The cells were resuspended in PBS and sorted using a BD FACSAria II instrument to obtain yeast with high binding ability to the PD-L1 antigen.
[0223] The yeast liquid with high binding ability to CAIX antigen obtained by magnetic bead and flow cytometry sorting was cultured overnight at 30°C and 225rpm in the amplification medium, and the yeast plasmid was extracted according to the yeast plasmid extraction kit (purchased from Tiangen). The plasmid was transformed into Top10 competent cells (purchased from Tiangen) by electroporation, coated with ampicillin resistant plates, and cultured at 37°C overnight. Single clones were selected for sequencing to obtain the VHH gene sequence.
[0224] Example 2 Construction of expression vector, protein expression and purification of CAIX nanobody
[0225] The CAIX VHH antibody coding sequence obtained by screening and the human IgG1 Fc segment coding sequence were constructed into a fusion protein expression sequence through homologous recombination. TM Expression System kit (purchased from Thermo), the fusion protein expression plasmid prepared in medium was transferred into Expi-CHO cells, the transfection method was in accordance with the product instructions, and the supernatant was collected after 5 days of cell culture and the target protein was purified by Protein A magnetic beads (purchased from GenScript) sorting method. The magnetic beads were resuspended in an appropriate volume of binding buffer (PBS + 0.1% Tween 20, pH 7.4) (1-4 times the volume of magnetic beads) and added to the sample to be purified, incubated at room temperature for 1 hour, and gently shaken during the period. The sample was placed on a magnetic stand (purchased from Beaver), the supernatant was discarded, and the magnetic beads were washed 3 times with binding buffer. Add elution buffer (0.1 M sodium citrate, pH 3.2) according to 3-5 times the volume of magnetic beads, shake at room temperature for 5-10 minutes, put it back on the magnetic rack, collect the elution buffer, transfer it to the collection tube added with neutralization buffer (1 M Tris, pH 8.54), mix well, and complete the preparation.
[0226] Example 3 Affinity detection of CAIX nanobody protein level
[0227] ForteBio affinity determination was performed according to the existing method (Estep, P et al., High throughput solution-based measurement of antibody-antigen affinity and epitope binning. MAbs, 2013. 5 (2): p. 270-8). In brief, the sensor was offline equilibrated in the analysis buffer for 30 min, then online for 60 s to establish a baseline, and the purified antibody obtained as described above was loaded online onto the AHQ sensor. The sensor was then placed in 100 nM PD-L1 antigen for 5 min, and then the sensor was transferred to PBS for dissociation for 5 min. A 1:1 binding model was used for kinetic analysis. The results are shown in Table 2.
[0228] Table 2 Affinity of candidate molecules
[0229]
[0230]
[0231] Example 4 Detection of CAIX Nanobody Cell Level Affinity
[0232] CHO cells overexpressing human CAIX (CHO-hCAIX cells) were generated by transfecting CAIX cDNA with the pCHO1.0 vector (purchased from Invitrogen). The cell density of CHO-CAIX cells was adjusted to 2×10 6 cel ls / ml, 100μL / well added to 96-well flow plate, centrifuged for later use. Dilute the purified CAIX antibody with PBS, start with 400nM and dilute 3 times for a total of 12 points, add 100μL / well of the diluted sample to the 96-well flow plate with cells, incubate at 4℃ for 30min, and wash twice with PBS. Add 100μL / well of Goat F(ab')2Anti-Human IgG-Fc(PE) (purchased from Abcam, ab98596) diluted 100 times with PBS, incubate at 4℃ for 30min, and wash twice with PBS. Add 100μl / well of PBS to resuspend the cells, detect on CytoFlex (Bechman) flow cytometer and calculate the corresponding MFI.
[0233] In the above method, the experimental results are as follows Figure 1 As shown in Table 3, all the purified samples of the present invention have binding activity with CHO-hCAIX cells, and the binding activity of some purified samples is higher than that of the single-chain control antibody whose sequence is from DANA Farber.
[0234] Table 3 EC50 of binding affinity of CAIX nanobody to CHO-hCAIX cells
[0235] no EC50(nM) DANA Farber 5.468 H-YE-03 7.344 H-YE-04 7.78 H-YE-05 8.795 H-YE-23 3.549 H-YE-24 3.055 H-YE-25 2.442 H-YE-26 4.457 H-YE-32 6.145 H-YE-33 2.779 H-YE-37 6.066 H-YE-40 4.743
[0236] Example 5 Protein level affinity detection of CAIX humanized nanobody
[0237] According to the sequences and affinity characteristics of the antibodies screened in the above examples, we selected three antibodies H-YE-05, H-YE-23 and H-YE-32 to complete the sequence humanization transformation. And the humanized sequence was used to complete the vector construction, expression and purification of the humanized antibody according to the method described in Example 2. Finally, H-YE-05 obtained 2 humanized modified antibodies, namely Hu-H-YE-05-D3 and Hu-H-YE-05-D4; H-YE-23 obtained 1 humanized modified antibody, named Hu-H-YE-23-D2; H-YE-32 obtained 2 humanized modified antibodies, namely Hu-H-YE-32-D6 and Hu-H-YE-32-D5; the purified humanized antibodies were used to complete the protein level affinity identification according to the method described in Example 3, and the results are shown in Table 4.
[0238] Table 4 Protein level affinity test results of CAIX humanized nanobody
[0239] no KD(M) Con(1 / Ms) Coffee (1 / s) H-YE-05 1.03E-08 1.55E+05 1.59E-03 Hu-H-YE-05-D3 1.03E-08 1.79E+05 1.85E-03 Hu-H-YE-05-D4 7.84E-09 1.81E+05 1.42E-03 H-YE-23 4.08E-09 1.36E+05 5.56E-04 Hu-H-YE-23-D2 6.68E-09 1.58E+05 1.05E-03 H-YE-32 3.69E-10 2.71E+05 1.00E-04 Hu-H-YE-32-D6 3.84E-10 2.60E+05 1.00E-04 Hu-H-YE-32-D5 8.20E-09 2.16E+05 1.77E-03 Gerentuximab 1.01E-09 9.86E+04 1.00E-04
[0240] Example 6 Detection of the binding ability of CAIX humanized nanobody to CHO-hCAIX cells and its species cross-recognition characteristics
[0241] The purified humanized antibody was subjected to affinity identification at the CHO-hCAIX cell level according to the method described in Example 4. The results are as follows: Figure 2 And as shown in Table 5.
[0242] Table 5 EC50 of binding affinity of humanized nanobodies to human CHO-hCAIX cells
[0243]
[0244]
[0245] To identify the affinity of the antibody to monkey CAIX (cyCAIX) at the cellular level, a cell line was constructed according to the method described in Example 4, and the affinity of the purified humanized antibody to CHO-cyCAIX at the cellular level was identified. Figure 3 And as shown in Table 6.
[0246] Table 6 EC50 of binding affinity of humanized nanobodies to monkey CHO-cyCAIX cells
[0247] no EC50(nM) H-YE-05 7.323 Hu-H-YE-05-D3 14.31 Hu-H-YE-05-D4 13.46 H-YE-23 6.552 Hu-H-YE-23-D2 25.11 H-YE-32 9.418 Hu-H-YE-32-D6 8.393 Hu-H-YE-32-D5 22.69 Gerentuximab 27.88
[0248] To identify the affinity of the antibody to mouse CAIX (mCAIX) at the cellular level, a cell line was constructed according to the method described in Example 4, and the affinity of the purified humanized antibody to CHO-mCAIX at the cellular level was identified. The results are as follows: Figure 4 And as shown in Table 7.
[0249] Table 7 EC50 of humanized nanobody binding to mouse CHO-mCAIX cells
[0250]
[0251]
[0252] discuss
[0253] Single-domain antibodies (sdAb), also known as nanobodies or heavy-chain antibodies (hcAb), are antibodies isolated from the serum of camelids and sharks, and their volume is about 1 / 10 of that of traditional antibodies. Unlike traditional antibodies, single-domain antibodies are composed only of heavy chains, and their antigen-binding region is only a single domain connected to the Fc region through a hinge region, and this antigen-binding region still has the function of binding to the antigen after being separated from the antibody. Single-domain antibodies have the characteristics of small molecular weight and good stability. Compared with traditional common normal antibodies in terms of drug research and development and diagnostic reagent development, they have many advantages such as good tissue infiltration, flexible administration methods, high degree of humanization, and easy recombinant protein transformation.
[0254] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
[0255] Sequence information of the present invention:
[0256] 1Amino acid (AA) sequence of CAIX-targeting nanobody:
[0257]
[0258]
[0259] 2DNA sequence of CAIX-targeting nanoantibody:
[0260]
[0261]
[0262] 3. Amino acid (AA) sequence, nucleotide sequence (DNA) and sequence numbering of CDR1-3 of CAIX-targeting nanobody
[0263] clone no CDR1 CDR2 CDR3 amino acid sequence Nucleoside sequence H-YE-03 1 2 3 4 5 H-YE-04 6 7 8 9 10 H-YE-05 11 12 13 14 15 H-YE-23 16 17 18 19 20 H-YE-24 21 22 23 24 25 H-YE-25 26 27 28 29 30 H-YE-26 31 32 33 34 35 H-YE-32 36 37 38 39 40 H-YE-33 41 42 43 44 45 H-YE-37 46 47 48 49 50 H-YE-38 51 52 53 54 55 H-YE-40 56 57 58 59 60
[0264] 4. Amino acid sequence encoding humanized CAIX nanobody
[0265] 5. Humanized CAIX Nanobody Encoding Nucleotide Sequence
[0266]
[0267] 6. Sequence numbering of the amino acid sequence and encoding nucleotide sequence of humanized CAIX nanobody
[0268]
[0269] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application. Sequence Listing <110> Biomis Biotechnology (Zhuhai) Co., Ltd. <120> Nanobodies targeting CAIX antigen and their applications <130> IDC220034 <150> CN201910853699.9 <151> 2019-09-10 <160> 93 <170> PatentIn version 3.5 <210> 1 <211> 8 <212> PRT <213> Artificial sequence <400> 1 Thr Ser Ser Phe Asn Phe Gln Thr 1 5 <210> 2 <211> 7 <212> PRT <213> Artificial sequence <400> 2 Ile Thr Ser Arg Ala Ile Thr 1 5 <210> 3 <211> 8 <212> PRT <213> Artificial sequence <400> 3 Asn Ala Ala Trp Ile Gly Asp Tyr 1 5 <210> 4 <211> 114 <212> PRT <213> Artificial sequence <400> 4 Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Ser Thr Ser Ser Phe Asn Phe Gln 20 25 30 Thr Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45 Ala Thr Ile Thr Ser Arg Ala Ile Thr Asn Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Ala Lys Thr Val Ser Leu 65 70 75 80 Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn 85 90 95 Ala Ala Trp Ile Gly Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val 100 105 110 Ser Ala <210> 5 <211> 342 <212> DNA <213> Artificial sequence <400> 5 caggtgcagc tgcaggagtc tgggggaggc ttggtgcagc ctggggggtc tctgagactc 60 tcctgtacag cctctactag cagtttcaat ttccagacca tgggctggta ccgccaggct 120 ccagggaagc agcgcgagtt ggtcgcgaca attactagcc gtgctatcac aaactatgca 180 gactccgtga agggccgctt caccatctcc agagacaacg ccgcgaagac ggtgtctctg 240 caaatgaaca gccttaaacc tgaggacacg gccgtctatt actgtaatgc agcgtggatc 300 ggggactact ggggccaggg gacccaggtc accgtctccg ca 342 <210> 6 <211> 8 <212> PRT <213> Artificial sequence <400> 6 Thr Ser Ser Phe Asn Phe Gln Thr 1 5 <210> 7 <211> 7 <212> PRT <213> Artificial sequence <400> 7 Ile Thr Ser Arg Ala Ile Thr 1 5 <210> 8 <211> 8 <212> PRT <213> Artificial sequence <400> 8 Asn Ala Ala Trp Ile Gly Asp Tyr 1 5 <210> 9 <211> 114 <212> PRT <213> Artificial sequence <400> 9 Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Ser Thr Ser Ser Phe Asn Phe Gln 20 25 30 Thr Leu Gly Trp Tyr Arg Gln Ala Pro Gly Asn Gln Arg Glu Leu Val 35 40 45 Ala Thr Ile Thr Ser Arg Ala Ile Thr Asn Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Ala Lys Thr Val Ser Leu 65 70 75 80 Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn 85 90 95 Ala Ala Trp Ile Gly Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val 100 105 110 Ser Ser <210> 10 <211> 342 <212> DNA <213> Artificial sequence <400> 10 caggtgcagc tgcaggagtc tgggggaggc ttggtgcagc ctggggggtc tctgagactc 60 tcctgtacag cctctactag cagtttcaat ttccagacct tgggctggta ccgccaggct 120 ccagggaatc agcgcgagtt ggtcgcgaca attactagcc gtgctatcac aaactatgca 180 gactccgtga agggccgctt caccatctcc agagacaacg ccgcgaagac ggtgtctctg 240 caaatgaaca gccttaaacc tgaggacacg gccgtctatt actgtaatgc agcgtggatc 300 ggggactact ggggccaggg gacccaggtc accgtctcca gt 342 <210> 11 <211> 11 <212> PRT <213> Artificial sequence <400> 11 Gly Asn Ser Val Asn Ile Phe Ser Phe Ala Ala 1 5 10 <210> 12 <211> 7 <212> PRT <213> Artificial sequence <400> 12 Ile Thr Thr Thr Gly Gly Thr 1 5 <210> 13 <211> 8 <212> PRT <213> Artificial sequence <400> 13 Asn Ala Asp Tyr Leu Gln Asp Tyr 1 5 <210> 14 <211> 117 <212> PRT <213> Artificial sequence <400> 14 Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Arg Arg Leu Ser Cys Ala Ala Ser Gly Asn Ser Val Asn Ile Phe 20 25 30 Ser Phe Ala Ala Val Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg 35 40 45 Glu Leu Val Ala Val Ile Thr Thr Thr Gly Gly Thr Lys Tyr Ser Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Ala Lys Asn Thr 65 70 75 80 Val Leu Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Asn Ala Asp Tyr Leu Gln Asp Tyr Trp Gly Gln Gly Thr Gln 100 105 110 Val Thr Val Ser Ser 115 <210> 15 <211> 351 <212> DNA <213> Artificial sequence <400> 15 caggtgcagc tgcaggagtc tgggggaggc ttggtgcaac ctggggggtc tcgtcgactc 60 tcctgtgcag cctctggaaa ctctgtaaac atcttcagtt tcgctgccgt ggcctggtac 120 cgccaggctc cagggaagca gcgcgagttg gtcgcagtca ttactacgac aggtggcact 180 aagtattcag actccgtgaa gggccgattc accatctcca gagacagcgc caagaatacg 240 gtgcttctgc aaatgaacag cctgaaacct gaggacacgg ccgtctatta ctgtaatgca 300 gattatttac aggactactg gggccagggg acccaggtca ccgtctccag t 351 <210> 16 <211> 11 <212> PRT <213> Artificial sequence <400> 16 Gly Asn Ser Ala Asn Ile Phe Ser Phe Ala Ser 1 5 10 <210> 17 <211> 7 <212> PRT <213> Artificial sequence <400> 17 Ile Thr Ser Ala Gly Gly Thr 1 5 <210> 18 <211> 8 <212> PRT <213> Artificial sequence <400> 18 Asn Val Asp Tyr Leu Gln Asp Tyr 1 5 <210> 19 <211> 117 <212> PRT <213> Artificial sequence <400> 19 Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Ser Ala Asn Ile Phe 20 25 30 Ser Phe Ala Ser Val Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg 35 40 45 Glu Leu Val Ala Val Ile Thr Ser Ala Gly Gly Thr Lys Tyr Ser Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr 65 70 75 80 Ile Leu Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Asn Val Asp Tyr Leu Gln Asp Tyr Trp Gly Gln Gly Thr Gln 100 105 110 Val Thr Val Ser Ser 115 <210> 20 <211> 351 <212> DNA <213> Artificial sequence <400> 20 caggtgcagc tgcaggagtc tggaggaggc ttggtgcaac ctggggggtc tctaagactc 60 tcctgtgcag cctctggaaa ctctgctaac atcttcagtt tcgcgtccgt ggcctggtac 120 cgccaggctc cagggaaaca gcgcgagttg gtcgcagtga tcactagtgc aggtggcact 180 aagtattcag actccgtgaa gggccgattc accatctcca gagacaacgc caagaatacg 240 attcttctgc aaatgaacag cctgaaacct gaggacacgg ccgtctatta ctgtaatgta 300 gattatttac aggactactg gggccagggg acccaggtca ccgtctccag t 351 <210> 21 <211> 11 <212> PRT <213> Artificial sequence <400> twenty one Gly Asn Ser Val Asn Ile Phe Arg Phe Ala Ala 1 5 10 <210> twenty two <211> 7 <212> PRT <213> Artificial sequence <400> twenty two Ile Thr Ser Ala Gly Gly Thr 1 5 <210> twenty three <211> 8 <212> PRT <213> Artificial sequence <400> twenty three Asn Ala Asp Tyr Leu Gln Asp Tyr 1 5 <210> twenty four <211> 117 <212> PRT <213> Artificial sequence <400> twenty four Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Ser Val Asn Ile Phe 20 25 30 Arg Phe Ala Ala Met Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg 35 40 45 Glu Leu Val Ala Val Ile Thr Ser Ala Gly Gly Thr Lys Tyr Ser Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr 65 70 75 80 Val Leu Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Asn Ala Asp Tyr Leu Gln Asp Tyr Trp Gly Gln Gly Thr Gln 100 105 110 Val Thr Val Ser Ser 115 <210> 25 <211> 351 <212> DNA <213> Artificial sequence <400> 25 caggtgcagc tgcaggagtc tgggggaggc ttggtgcagc ctggggggtc tctaagactc 60 tcctgtgcag cctctggaaa ctctgtaaac atcttcagat tcgctgccat ggcctggtac 120 cgccaggctc cagggaagca gcgcgagttg gtcgcagtca ttactagtgc aggtggcact 180 aagtattcag actccgtgaa gggccgattc accatctcca gagacaacgc caagaatacg 240 gtgcttctgc aaatgaacag cctgaaacct gaggacacgg ccgtctatta ctgtaatgca 300 gattatttac aggactactg gggccagggg acccaggtca ccgtctccag t 351 <210> 26 <211> 11 <212> PRT <213> Artificial sequence <400> 26 Gly Asn Ser Val Asn Ile Phe Arg Phe Ala Ala 1 5 10 <210> 27 <211> 7 <212> PRT <213> Artificial sequence <400> 27 Ile Thr Thr Thr Gly Gly Thr 1 5 <210> 28 <211> 8 <212> PRT <213> Artificial sequence <400> 28 Asn Ala Asp Tyr Leu Gln Asp Tyr 1 5 <210> 29 <211> 117 <212> PRT <213> Artificial sequence <400> 29 Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Ser Val Asn Ile Phe 20 25 30 Arg Phe Ala Ala Met Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg 35 40 45 Glu Leu Val Ala Val Ile Thr Thr Thr Gly Gly Thr Lys Tyr Ser Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Ala Lys Asn Thr 65 70 75 80 Val Leu Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Asn Ala Asp Tyr Leu Gln Asp Tyr Trp Gly Gln Gly Thr Gln 100 105 110 Val Thr Val Ser Ser 115 <210> 30 <211> 351 <212> DNA <213> Artificial sequence <400> 30 caggtgcagc tgcaggagtc tggaggaggc ttggtgcaac ctggggggtc tctaagactc 60 tcctgtgcag cctctggaaa ctctgtaaac atcttcagat tcgctgccat ggcctggtac 120 cgccaggctc cagggaagca gcgcgagttg gtcgcagtca ttactacgac aggtggcact 180 aagtattcag actccgtgaa gggccgattc accatctcca gagacagcgc caagaatacg 240 gtgcttctgc aaatgaacag cctgaaacct gaggacacgg ccgtctatta ctgtaatgca 300 gattatttac aggactactg gggccagggg acccaggtca ccgtctccag t 351 <210> 31 <211> 11 <212> PRT <213> Artificial sequence <400> 31 Gly Asn Ser Val Asn Ile Phe Arg Phe Ala Thr 1 5 10 <210> 32 <211> 7 <212> PRT <213> Artificial sequence <400> 32 Ile Thr Ser Ala Gly Gly Thr 1 5 <210> 33 <211> 8 <212> PRT <213> Artificial sequence <400> 33 Asn Ala Asp Phe Leu Gln Asp Tyr 1 5 <210> 34 <211> 117 <212> PRT <213> Artificial sequence <400> 34 Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Ser Val Asn Ile Phe 20 25 30 Arg Phe Ala Thr Val Ala Trp Tyr Arg Gln Ala Pro Gly Glu Gln Arg 35 40 45 Glu Leu Val Ala Val Ile Thr Ser Ala Gly Gly Thr Lys Tyr Ser Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr 65 70 75 80 Val Leu Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Asn Ala Asp Phe Leu Gln Asp Tyr Trp Gly Gln Gly Thr Gln 100 105 110 Val Thr Val Ser Ser 115 <210> 35 <211> 351 <212> DNA <213> Artificial sequence <400> 35 caggtgcagc tgcaggagtc tgggggaggc ttggtgcagg ctggggggtc tctgagactc 60 tcctgtgcag cctctggaaa ctctgtgaac atcttcaggt tcgctaccgt agcctggtac 120 cgccaggctc caggggagca gcgcgagttg gtcgcagtca ttactagtgc aggtggcact 180 aagtattcag actccgtgaa gggccgattc accatctcca gagacaacgc caagaatacg 240 gtgcttctgc aaatgaacag cctgaaacct gaggacacgg ccgtctatta ttgtaatgca 300 gattttttac aggactactg gggccagggg acccaggtca ccgtctccag t 351 <210> 36 <211> 11 <212> PRT <213> Artificial sequence <400> 36 Gly Gly Ala Arg Asn Ile Phe Ser Phe Ala Ala 1 5 10 <210> 37 <211> 7 <212> PRT <213> Artificial sequence <400> 37 Ile Thr Ser Ala Gly Gly Thr 1 5 <210> 38 <211> 8 <212> PRT <213> Artificial sequence <400> 38 Asn Ala Asp Tyr Tyr Gln Asp Tyr 1 5 <210> 39 <211> 117 <212> PRT <213> Artificial sequence <400> 39 Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Ala Arg Asn Ile Phe 20 25 30 Ser Phe Ala Ala Met Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg 35 40 45 Glu Leu Val Ala Val Ile Thr Ser Ala Gly Gly Thr Gln Tyr Ser Ser 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr 65 70 75 80 Val Leu Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Asn Ala Asp Tyr Tyr Gln Asp Tyr Trp Gly Gln Gly Thr Gln 100 105 110 Val Thr Val Ser Ser 115 <210> 40 <211> 351 <212> DNA <213> Artificial sequence <400> 40 caggtgcagc tgcaggagtc tgggggaggc ttggtgcaac ctggggggtc tctaagactc 60 120. tcctgtgcag cctctggagg cgctagaaac atcttcagct tcgctgccat ggcctggtac cgccaggctc cgggagca gcgcgagttg gtcgcagtca ttactagtgc aggaggcacg cagtattca gctccgtga gggccgattc accatctcca gagacaacgc caagaaaacg gtattgctgc aaatgaacag cctgaaacct gaggacacgg ccgtctatta ctgtaatgca gattattatc aggactactg gggccagggg acccaggtca ccgtctccag t 351 <210> 41 <211> 8 <212> PRT <213> Artificial sequence (Artificial sequence) <400> 41 Gly Gly Asp Phe Arg Phe Tyr Asp 1 5 <210> 42 <211> 7 <212> PRT <213> Artificial sequence (Artificial sequence) <400> 42 Ile Thr Thr Arg Gly Tyr Thr 1 5 <210> 43 <211> 12 <212> PRT <213> Artificial sequence (Artificial sequence) <400> 43 Ser Ala Ser His Phe Leu Gly Gly Arg Ile Asp Tyr 1 5 10 <210> 44 <211> 118 <212> PRT <213> Artificial sequence <400> 44 Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Asp Phe Arg Phe Tyr 20 25 30 Asp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45 Ala Gly Ile Thr Thr Arg Gly Tyr Thr Asn Tyr Ala Asp Val Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu 65 70 75 80 Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Ser Cys Ser 85 90 95 Ala Ser His Phe Leu Gly Gly Arg Ile Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Gln Val Thr Val Ser Ser 115 <210> 45 <211> 354 <212> DNA <213> Artificial sequence <400> 45 caggtgcagc tgcaggagtc tggaggaggc ttggtgcagc ctggggggtc tctgagactc 60 caggtgcagc tgcaggagtc tggaggaggc ttggtgcagc ctggggggtc tctgagactc 60 tcctgtgcag cctctggagg ggacttcagg ttctatgaca tgggctggta ccgccaggct 120 tcctgtgcag cctctggagg ggacttcagg ttctatgaca tgggctggta ccgccaggct 120 ccagggaagc agcgcgagtt ggtcgcaggt attactactc gtggctacac caactatgca 180 ccagggaagc agcgcgagtt ggtcgcaggt attactactc gtggctacac caactatgca 180 gacgtcgtga agggccgatt caccatctcc agagacaacg ccaagaacac ggtgtatctg 240 gacgtcgtga agggccgatt caccatctcc agagacaacg ccaagaacac ggtgtatctg 240 gaaatgaaca gcctgaaacc tgaggacacg gccgtctatt cctgtagtgc aagtcacttc 300 gaaatgaaca gcctgaaacc tgaggacacg gccgtctatt cctgtagtgc aagtcacttc 300 ctgggcggga gaatagacta ctggggccag gggacccagg tcaccgtctc cagt 354 ctgggcggga gaatagacta ctggggccag gggacccagg tcaccgtctc cagt 354 <210> 46<210> 46 <211> 8<211> 8 <212> PRT<212> PRT <213> 人工序列(Artificial sequence)<213> Artificial sequence <400> 46<400> 46 Gly Arg Thr Phe Ser Thr Tyr Ala Gly Arg Thr Phe Ser Thr Tyr Ala 1 5 1 5 <210> 47<210> 47 <211> 8<211> 8 <212> PRT <212> PRT <213> 人工序列(Artificial sequence) <213> Artificial sequence <400> 47 <400> 47 Ile Ser Trp Ser Gly Gly Ser Thr Ile Ser Trp Ser Gly Gly Ser Thr 1 5 1 5 <210> 48 <210> 48 <211> 20 <211> 20 <212> PRT <212> PRT <213> 人工序列(Artificial sequence) <213> Artificial sequence <400> 48 <400> 48 Ala Ala Glu Gly Ile Tyr Asn Ser Gly Ser Ser Tyr His Asp Ala Asn 1 5 10 15 Gly Tyr Asp Tyr 20 <210> 49 <211> 127 <212> PRT <213> Artificial sequence <400> 49 Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Met His Asp Gly Asp 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Thr Tyr 20 25 30 Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45 Ala Ala Ile Ser Trp Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ala Glu Gly Ile Tyr Asn Ser Gly Ser Ser Tyr His Asp Ala Asn 100 105 110 Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 125 <210> 50 <211> 381 <212> DNA <213> Artificial sequence <400> 50 caggtgcagc tgcaggagtc tggaggagga ttgatgcatg atggggactc tctgagactc 60 tcctgtgcag cctctggacg caccttcagt acctatgcca tgggctggtt ccgccaggct 120 ccagggaagg agcgtgagtt tgtagcagct attagctgga gtggtggtag cacatactat 180 gcagactccg tgaagggccg attcaccatc tccagagaca acgccaagaa cacggtgtat 240 ctgcaaatga acagcctgaa acctgaggac acggccgttt attactgtgc agcagagggg 300 atatacaata gtggtagttc gtaccatgac gcgaacgggt atgactactg gggccagggg 360 acccaggtca ccgtctccag t 381 <210> 51 <211> 8 <212> PRT <213> Artificial sequence <400> 51 Arg Phe Thr Leu Asp Tyr Tyr Ala 1 5 <210> 52 <211> 8 <212> PRT <213> Artificial sequence <400> 52 Ile Ser Trp Ser Gly Gly Thr Thr 1 5 <210> 53 <211> 13 <212> PRT <213> Artificial sequence <400> 53 Ala Ala Gly Arg Gln Leu Glu Trp Arg Thr Tyr Asp Tyr 1 5 10 <210> 54 <211> 120 <212> PRT <213> Artificial sequence <400> 54 Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Met Gln Pro Gly Gly 1 5 10 15 Ser Leu Thr Leu Ser Cys Ala Val Pro Arg Phe Thr Leu Asp Tyr Tyr 20 25 30 Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45 Ala Ala Ile Ser Trp Ser Gly Gly Thr Thr Gln Tyr Ser Asp Ser Ala 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Gly Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Ala Ala Gly Arg Gln Leu Glu Trp Arg Thr Tyr Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Gln Val Thr Val Ser Ser 115 120 <210> 55 <211> 360 <212> DNA <213> Artificial sequence <400> 55 caggtgcagc tgcaggagtc tgggggaggc ttgatgcagc ctggggggtc tctgacgctc 60 tcctgtgcag tccctagatt cactttggat tattatgcca taggctggtt ccggcaggcc 120 ccagggaagg agcgtgaatt tgtagcagct attagctgga gtggtggtac aacacagtat 180 tcagactccg cgaagggccg attcaccatc tccagagaca acagcaagaa tacggggtat 240 ctgcaaatga acagcctgaa acctgaggac acggcgactt attactgtgc agcaggtcgc 300 caactggagt ggaggacgta tgactactgg ggccagggga cccaggtcac cgtctccagt 360 <210> 56 <211> 8 <212> PRT <213> Artificial sequence <400> 56 Gly Arg Thr Phe Ser Ser Tyr Ala 1 5 <210> 57 <211> 8 <212> PRT <213> Artificial sequence <400> 57 Ile Ser Trp Asn Gly Gly Ser Thr 1 5 <210> 58 <211> 16 <212> PRT <213> Artificial sequence <400> 58 Ala Ala Glu His Asp Leu Gly Glu Leu Ala Gly Thr Gly Tyr Asp Tyr 1 5 10 15 <210> 59 <211> 123 <212> PRT <213> Artificial sequence <400> 59 Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30 Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45 Ala Thr Ile Ser Trp Asn Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ala Glu His Asp Leu Gly Glu Leu Ala Gly Thr Gly Tyr Asp Tyr 100 105 110 Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 <210> 60 <211> 369 <212> DNA <213> Artificial sequence <400> 60 caggtgcagc tgcaggagtc tggaggagga ttggtgcagg ctgggggctc tctgagactc 60 tcctgtgcag cctctggacg caccttcagt agctatgcca tgggctggtt ccgccaggct 120 ccagggaagg agcgtgagtt tgtagcaact attagctgga atggtggtag cacatactat 180 gcagactccg tgaagggccg attcaccatc tccagagaca acgccaagaa cacggtgtat 240 ctgcaaatga acagcctgaa acctgaggac acggccgttt attactgtgc agcagaacat 300 gatttggggg agctggcggg aactggttat gactactggg gccaggggac ccaggtcacc 360 gtctccagt 369 <210> 61 <211> 117 <212> PRT <213> Artificial sequence <400> 61 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Ser Val Asn Ile Phe 20 25 30 Ser Phe Ala Ala Met Ser Trp Tyr Arg Gln Ala Pro Gly Lys Gly Leu 35 40 45 Glu Leu Val Ala Val Ile Thr Thr Thr Gly Gly Thr Lys Tyr Ser Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Asn Ala Asp Tyr Leu Gln Asp Tyr Trp Gly Gln Gly Thr Gln 100 105 110 Val Thr Val Ser Ser 115 <210> 62 <211> 351 <212> DNA <213> Artificial sequence <400> 62 gaggtgcagc tgctggagag cggcggcggc ctggtgcagc ccggcggcag cctgaggctg 60 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly agctgcgccg ccagcggcaa cagcgtgaac atcttcagct tcgccgccat gagctggtac 120 Ser Arg Arg Leu Ser Cys Ala Ala Ser Gly Asn Ser Val Asn Ile Phe aggcaggccc ccggcaaggg cctggagctg gtggccgtga tcaccaccac cggcggcacc 180 Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Val Ile Thr Thr Thr Gly Gly Thr aagtacagcg acagcgtgaa gggcaggttc accatcagca gggacaacag caagaacacc 240 Lys Tyr Ser Asp Ser Val Lys Gly Gln Phe Thr Ile Gln Ser Gly Asp Asn Ser Lys Asn Thr ctgtacctgc agatgaacag cctgagggcc gaggacaccg ccgtgtacta ctgcaacgcc 300 Leu Tyr Leu Gln Asp Glu Gln Pro Glu Gly Arg Asp Thr Ala Val Tyr Tyr Cys Asn Ala gactacctgc aggactactg gggccagggc acccaggtga ccgtgagcag c 351 Asp Tyr Leu Gln Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser <210> 63 <211> 117 <212> PRT <213> Artificial sequence <400> 63 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Arg Arg Leu Ser Cys Ala Ala Ser Gly Asn Ser Val Asn Ile Phe 20 25 30 Ser Phe Ala Ala Val Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg 35 40 45 Glu Leu Val Ala Val Ile Thr Thr Thr Gly Gly Thr Lys Tyr Ser Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Ser Lys Asn Thr 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Asn Ala Asp Tyr Leu Gln Asp Tyr Trp Gly Gln Gly Thr Gln 100 105 110 Val Thr Val Ser Ser 115 <210> 64 <211> 351 <212> DNA <213> Artificial sequence <400> 64 gaggtgcagc tgctggagag cggcggcggc ctggtgcagc ccggcggcag caggaggctg 60 agctgcgccg ccagcggcaa cagcgtgaac atcttcagct tcgccgccgt ggcctggtac 120 aggcaggccc ccggcaagca gagggagctg gtggccgtga tcaccaccac cggcggcacc 180 aagtacagcg acagcgtgaa gggcaggttc accatcagca gggacagcag caagaacacc 240 gtgtacctgc agatgaacag cctgagggcc gaggacaccg ccgtgtacta ctgcaacgcc 300 gactacctgc aggactactg gggccagggc acccaggtga ccgtgagcag c 351 <210> 65 <211> 117 <212> PRT <213> Artificial sequence <400> 65 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Asn Ser Ala Asn Ile Phe 20 25 30 Ser Phe Ala Ser Val Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gly Leu 35 40 45 Glu Leu Val Ser Val Ile Thr Ser Ala Gly Gly Thr Lys Tyr Ser Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Asn Val Asp Tyr Leu Gln Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 66 <211> 351 <212> DNA <213> Artificial sequence <400> 66 caggtgcagc tggtggagag cggcggcggc ctggtgcagc ccggcggcag cctgaggctg 60 agctgcagcg ccagcggcaa cagcgccaac atcttcagct tcgccagcgt ggcctggtac 120 aggcaggccc ccggcaaggg cctggagctg gtgagcgtga tcaccagcgc cggcggcacc 180 aagtacagcg acagcgtgaa gggcaggttc accatcagca gggacaacag caagaacacc 240 ctgtacctgc agatgaacag cctgagggcc gaggacaccg ccgtgtacta ctgcaacgtg 300 gactacctgc aggactactg gggccagggc accctggtga ccgtgagcag c 351 <210> 67 <211> 117 <212> PRT <213> Artificial sequence <400> 67 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Gly Ala Arg Asn Ile Phe 20 25 30 Ser Phe Ala Ala Met Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gly Leu 35 40 45 Glu Leu Val Ala Val Ile Thr Ser Ala Gly Gly Thr Gln Tyr Ser Ser 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Asn Ala Asp Tyr Tyr Gln Asp Tyr Trp Gly Gln Gly Thr Gln 100 105 110 Val Thr Val Ser Ser 115 <210> 68 <211> 351 <212> DNA <213> Artificial sequence <400> 68 caggtgcagc tggtggagag cggcggcggc ctggtgcagc ccggcggcag cctgaggctg 60 agctgcagcg ccagcggcgg cgccaggaac atcttcagct tcgccgccat ggcctggtac 120 aggcaggccc ccggcaaggg cctggagctg gtggccgtga tcaccagcgc cggcggcacc 180 cagtacagca gcagcgtgaa gggcaggttc accatcagca gggacaacag caagaagacc 240 ctgtacctgc agatgaacag cctgagggcc gaggacaccg ccgtgtacta ctgcaacgcc 300 gactactacc aggactactg gggccagggc acccaggtga ccgtgagcag c 351 <210> 69 <211> 117 <212> PRT <213> Artificial sequence <400> 69 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Gly Ala Arg Asn Ile Phe 20 25 30 Ser Phe Ala Ala Met His Trp Tyr Arg Gln Ala Pro Gly Lys Gly Leu 35 40 45 Glu Leu Val Ala Val Ile Thr Ser Ala Gly Gly Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Asn Ala Asp Tyr Tyr Gln Asp Tyr Trp Gly Gln Gly Thr Gln 100 105 110 Val Thr Val Ser Ser 115 <210> 70 <211> 351 <212> DNA <213> Artificial sequence <400> 70 60. caggtgcagc tggtggagag cggcggcggc ctggtgcagc ccggcggcag cctgaggctg agctgcagcg ccagcggcgg cgccaggac atcttcagct tcgccgccat gcactggtac aggcaggccc ccggcaaggg cctggagctg gtggccgtga tcaccagcgc cggcggcacc 180 tactacgccg acagcgtgaa gggcaggttc accatcagca gggacaacag caagaagacc ctgtacctgc agatgaacag cctgagggcc gaggacaccg ccgtgtacta ctgcaacgcc gactactacc aggactactg gggccagggc acccaggtga ccgtgagcag c <210> 71 <211> 25 <212> PRT <213> Artificial sequence (Artificial sequence) <400> 71 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ser 20 25 <210> 72 <211> 17 <212> PRT <213> Artificial sequence (Artificial sequence) <400> 72 Met Ser Trp Tyr Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu Val Ala 1 5 10 15 Val <210> 73 <211> 38 <212> PRT <213> Artificial sequence <400> 73 Lys Tyr Ser Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 1 5 10 15 Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp 20 25 30 Thr Ala Val Tyr Tyr Cys 35 <210> 74 <211> 11 <212> PRT <213> Artificial sequence <400> 74 Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 1 5 10 <210> 75 <211> 25 <212> PRT <213> Artificial sequence <400> 75 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Arg Arg Leu Ser Cys Ala Ala Ser 20 25 <210> 76 <211> 17 <212> PRT <213> Artificial sequence <400> 76 Val Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala 1 5 10 15 Val <210> 77 <211> 38 <212> PRT <213> Artificial sequence <400> 77 Lys Tyr Ser Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser 1 5 10 15 Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp 20 25 30 Thr Ala Val Tyr Tyr Cys 35 <210> 78 <211> 11 <212> PRT <213> Artificial sequence <400> 78 Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 1 5 10 <210> 79 <211> 25 <212> PRT <213> Artificial sequence <400> 79 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser 20 25 <210> 80 <211> 17 <212> PRT <213> Artificial sequence <400> 80 Val Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu Val Ser 1 5 10 15 Val <210> 81 <211> 38 <212> PRT <213> Artificial sequence <400> 81 Lys Tyr Ser Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 1 5 10 15 Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp 20 25 30 Thr Ala Val Tyr Tyr Cys 35 <210> 82 <211> 11 <212> PRT <213> Artificial sequence <400> 82 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 1 5 10 <210> 83 <211> 25 <212> PRT <213> Artificial sequence <400> 83 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser 20 25 <210> 84 <211> 17 <212> PRT <213> Artificial sequence <400> 84 Met Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu Val Ala 1 5 10 15 Val <210> 85 <211> 38 <212> PRT <213> Artificial sequence <400> 85 Gln Tyr Ser Ser Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 1 5 10 15 Ser Lys Lys Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp 20 25 30 Thr Ala Val Tyr Tyr Cys 35 <210> 86 <211> 11 <212> PRT <213> Artificial sequence <400> 86 Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 1 5 10 <210> 87 <211> 25 <212> PRT <213> Artificial sequence <400> 87 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ser Ala Ser 20 25 <210> 88 <211> 17 <212> PRT <213> Artificial sequence <400> 88 Met His Trp Tyr Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu Val Ala 1 5 10 15 Val <210> 89 <211> 38 <212> PRT <213> Artificial sequence <400> 89 Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 1 5 10 15 Ser Lys Lys Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp 20 25 30 Thr Ala Val Tyr Tyr Cys 35 <210> 90 <211> 11 <212> PRT <213> Artificial sequence <400> 90 Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 1 5 10 <210> 91 <211> 9 <212> PRT <213> artificial <220> <223> linker 1 <400> 91 Gly Gly Gly Gly Ser Gly Gly Gly Ser 1 5 <210> 92 <211> 2 <212> PRT <213> artificial <220> <223> linker 2 <400> 92 Gly Ser 1 <210> 93 <211> 5 <212> PRT <213> artificial <220> <223> linker 3 <400> 93 Gly Gly Gly Gly Ser 1 5
Claims
1. A VHH chain of an anti-CAIX single domain antibody, wherein the complementarity determining region (CDR) of the VHH chain comprises: (1) CDR1 shown in SEQ ID NO.11, CDR2 shown in SEQ ID NO.12, and CDR3 shown in SEQ ID NO.13; or, (2) CDR1 shown in SEQ ID NO.36, CDR2 shown in SEQ ID NO.37, and CDR3 shown in SEQ ID NO.
38.
2. The VHH chain of the anti-CAIX single domain antibody of claim 1, wherein the VHH chain comprises: (1) CDR1 shown in SEQ ID NO.11, CDR2 shown in SEQ ID NO.12, and CDR3 shown in SEQ ID NO.13; and FR1 shown in SEQ ID NO.75, FR2 shown in SEQ ID NO.76, FR3 shown in SEQ ID NO.77, and FR4 shown in SEQ ID NO.78; or, (2) CDR1 shown in SEQ ID NO.36, CDR2 shown in SEQ ID NO.37, and CDR3 shown in SEQ ID NO.38; and FR1 shown in SEQ ID NO.83, FR2 shown in SEQ ID NO.84, FR3 shown in SEQ ID NO.85, and FR4 shown in SEQ ID NO.
86.
3. An anti-CAIX single domain antibody, characterized in that It is a single domain antibody against the CAIX epitope, and the sequence of the VHH chain is as shown in claim 1 or 2.
4. The anti-CAIX single domain antibody according to claim 3, characterized in that The amino acid sequence of the VHH chain of the single-domain antibody is shown in SEQ ID NO. 14, 39, 61, 63, 67 or 69.
5. A polynucleotide, characterized in that The polynucleotide encodes a protein selected from the group consisting of: the VHH chain of the anti-CAIX single domain antibody of claim 1 or 2, and the anti-CAIX single domain antibody of claim 3 or 4.
6. An expression vector, characterized in that: The expression vector contains the polynucleotide according to claim 5.
7. A host cell, characterized in that The host cell contains the expression vector according to claim 6, or the polynucleotide according to claim 5 is integrated into its genome.
8. A method for producing an anti-CAIX single domain antibody, characterized in that: Includes steps: (a) culturing the host cell of claim 7 under conditions suitable for producing the single domain antibody, thereby obtaining a culture containing the anti-CAIX single domain antibody; as well as (b) isolating or recovering the anti-CAIX single domain antibody from the culture; and (c) Optionally, purifying the CAIX single domain antibody obtained in step (b).
9. An immunoconjugate, characterized in that: The immunoconjugate consists of: (a) the VHH chain of the anti-CAIX single domain antibody according to claim 1 or 2, or the anti-CAIX single domain antibody according to claim 3 or 4; and (b) a conjugated moiety selected from the group consisting of a detectable label, a drug, a toxin, a cytokine, a radionuclide, an enzyme, a gold nanoparticle, a nanomagnetic particle, a viral coat protein or a VLP.
10. Use of the VHH chain of the anti-CAIX single domain antibody of claim 1 or 2, or the anti-CAIX single domain antibody of claim 3 or 4 for preparing an antibody-drug conjugate (ADC), a monoclonal antibody and / or a multispecific antibody targeting CAIX antigen.
11. A recombinant protein, characterized in that The recombinant protein is composed of: (i) the VHH chain of the anti-CAIX single domain antibody according to claim 1 or 2 or the anti-CAIX single domain antibody according to claim 3 or 4; and (ii) optionally a tag sequence to facilitate expression and / or purification.
12. A method for detecting CAIX protein in a sample in vitro for non-diagnostic purposes, characterized in that: The method comprises the steps of: (1) contacting a sample with the VHH chain of the anti-CAIX single domain antibody of claim 1 or 2, the single domain antibody of claim 3 or 4, or the immunoconjugate of claim 9; (2) Detecting whether an antigen-antibody complex is formed, wherein the formation of the complex indicates the presence of CAIX protein in the sample.
13. A CAIX protein detection reagent, characterized in that: The detection reagent comprises: (i) the VHH chain of the anti-CAIX single domain antibody of claim 1 or 2, the single domain antibody of claim 3 or 4, or the immunoconjugate of claim 9; and (ii) A carrier that is acceptable in detection.
14. A kit for detecting CAIX protein, characterized in that: The kit contains the immunoconjugate according to claim 9 or the detection reagent according to claim 13, and instructions.
15. A use of the immunoconjugate according to claim 9, characterized in that: Used for preparing contrast agent for in vivo detection of CAIX protein.
